TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33076964
Drug: Intramuscular 120
Normalized name: Intramuscular Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 120 mg methylprednisolone followed by methotrexate
Study: 36205701
Drug: Single-point injection
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-point injection of 2 U of botulinum toxin type A per side (simplified method)
Study: 34481432
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cytoflavin daily for 10 days
Study: 34481432
Drug: Standard post-COVID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post-COVID rehabilitation protocol (pulse magnetic therapy, inhalation therapy, aeroion therapy, infrared laser therapy, course aerobic training, psychotherapy, and standard drug therapy)
Study: 32726268
Drug: Lactate ≥4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate ≥4 mmol/L
Study: 32726268
Drug: Lactate ≥7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate ≥7 mmol/L
Study: 32726268
Drug: Lactate <4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate <4 mmol/L
Study: 35511718
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg 3 times/day)
Study: 32895056
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with low-molecular-weight heparins/unfractionated heparin subcutaneously
Study: 32457078
Drug: 250 mcg
Normalized name: Nplate 250 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg methylcobalamin
Study: 32457078
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg (quasi control)
Study: 35986460
Drug: Remin Pro
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remin Pro Forte (3-month program of hydroxyapatite, fluoride, xylitol, ginger, curcuma-containing cream)
Study: 35986460
Drug: Remin Pro
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remin Pro (3-month cream regimen including hydroxyapatite and fluoride, xylitol)
Study: 33608405
Drug: Early closure
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early closure strategy (between 30 and 40 days from rectal surgery)
Study: 33608405
Drug: Late closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late closure strategy (after the end of adjuvant therapy)
Study: 33725262
Drug: Prenatal exposure
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exposure to maternal autoantibodies or anti-rheumatic drugs
Study: 32281113
Drug: Proximal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal corticosteroid injection (40 mg of methylprednisolone injected 2 cm proximal to the wrist crease)
Study: 32281113
Drug: Distal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal corticosteroid injection (40 mg of methylprednisolone injected 2 to 3 cm distal to the wrist crease)
Study: 32281113
Drug: Proximal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal corticosteroid injection
Study: 32281113
Drug: Distal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal corticosteroid injection
Study: 33565243
Drug: Low-power fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power fractional CO2 laser combined with topical tranexamic acid (TXA) applied twice a day for 3 weeks, four times in total.
Study: 33565243
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified what treatment was used).
Study: 33673786
Drug: Freeze all
Normalized name: Freez Eez
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze all treatment
Study: 32171760
Drug: Post-amendment inclusion
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-amendment inclusion criteria requiring elevated natriuretic peptides (B-type natriuretic peptide ≥200 ng/l or N-terminal pro-B-type natriuretic peptide ≥800 ng/l)
Study: 36094645
Drug: Donanemab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donanemab (700 mg for the first 3 doses, then 1400 mg every 4 weeks for up to 72 weeks)
Study: 36070709
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for gestational diabetes
Study: 35718032
Drug: ZnO–NF1 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnO–NF1 (1.5 g/L photocatalyst)
Study: 35718032
Drug: ZnO–NF2 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnO–NF2 (1.5 g/L photocatalyst)
Study: 35718032
Drug: ZnO–NF2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnO–NF2 (2 g/L photocatalyst)
Study: 32920065
Drug: Riboflavin (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (1.6 mg/d for 16 weeks)
Study: 34371324
Drug: Ketadex (dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketadex (dexmedetomidine 0.7 μg/kg and ketamine 1 mg/kg)
Study: 34371324
Drug: Ketofol (propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketofol (propofol 0.5 mg/kg and ketamine 0.5 mg/kg)
Study: 34371324
Drug: Ketamine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine alone (1 mg/kg)
Study: 32825989
Drug: Osteopathic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatments (OTs)
Study: 36117146
Drug: Topical gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical gabapentin 10%
Study: 35310422
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg mirtazapine tablet
Study: 35310422
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone diluted in 100 ml of saline infusion
Study: 33268401
Drug: Flexible gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible gonadotropin-releasing hormone (GnRH) antagonist protocol
Study: 33268401
Drug: Both PPOS
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both PPOS and GnRH antagonist protocols
Study: 34717820
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg twice daily for 10 days)
Study: 34058110
Drug: Medical and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical and lifestyle therapy
Study: 35487475
Drug: Ca(OH)2 +
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 + saline solution (n = 10)
Study: 35487475
Drug: Ca(OH)2 +
Normalized name: IMMUNOGLOBULIN G (HUMAN-MOUSE MONOCLONAL CA2 HEAVY CHAIN ANTI-HUMAN TUMOR NECROSIS FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL CA2 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2 + 2% chlorhexidine-gel (n = 10)
Study: 35610603
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy‐ Enhanced (CBT‐E)
Study: 33432016
Drug: Self-administered survey
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered survey on waste management awareness
Study: 34243076
Drug: Veliparib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (120 mg orally BID) with carboplatin (AUC 6) and paclitaxel (80 mg/m2)
Study: 34243076
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with carboplatin (AUC 6) and paclitaxel (80 mg/m2)
Study: 34243076
Drug: Veliparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (300 mg BID, increasing to 400 mg BID if tolerated)
Study: 33836814
Drug: Single-injection ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection ultrasound-guided thoracic paravertebral block (US-TPVB) with 20 ml of 0.25% ropivacaine
Study: 33836814
Drug: Oblique subcostal
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblique subcostal transversus abdominis plane (TAP) block with 20 ml of 0.25% ropivacaine
Study: 33836814
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic infiltration (LAI) with 40 ml of 0.25% ropivacaine
Study: 36066078
Drug: Indacaterol (27.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol (27.5 μg) plus glycopyrrolate (15.6 μg) twice daily for 12 weeks
Study: 32176061
Drug: Apatinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib combined with carboplatin-paclitaxel or concurrent chemo-brachytherapy (CCBT)
Study: 32176061
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone or CCBT
Study: 32176061
Drug: Apatinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib combined with chemotherapy or CCBT
Study: 35501515
Drug: Post-infusion cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-infusion cooling time (PICT) of 45 min
Study: 35501515
Drug: Post-infusion cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-infusion cooling time (PICT) of 20 min
Study: 35501515
Drug: Standard post-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post-infusion cooling time (PICT) of 90 min
Study: 36348385
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg twice daily as maintenance therapy
Study: 36348385
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg twice daily as treatment
Study: 36348385
Drug: Rucaparib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib (both maintenance and treatment)
Study: 33588088
Drug: CRRT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRRT at 70 ml/kg/h
Study: 33588088
Drug: CRRT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRRT at 35 ml/kg/h
Study: 35123660
Drug: Baricitinib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (4 mg) once daily for up to 14 days plus standard of care
Study: 32552774
Drug: Oral fluralaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluralaner (Bravecto®) administered at a minimum dose of 25 mg/kg body weight, one time on Day 0.
Study: 35853489
Drug: Monthly injection
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly injection (AM)
Study: 35853489
Drug: Injection every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection every other month (AEOM)
Study: 33027403
Drug: Weekly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text messages
Study: 33027403
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message intervention (both weekly and biweekly)
Study: 35643951
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (HDP) 60 mg daily (tapered to 0 mg within 12 weeks)
Study: 35643951
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (LDP) 10 mg daily (tapered to 0 mg within 12 weeks)
Study: 35643951
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (HDP)
Study: 35643951
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (LDP)
Study: 32522106
Drug: 5-fluorouracil/leucovorin (5-FU/LV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/leucovorin (5-FU/LV) chemotherapy
Study: 33296079
Drug: High-protein enteral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein enteral nutrition (63 or 100 g/L protein) for ≤28 days
Study: 33296079
Drug: Usual practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual practice enteral nutrition (lower protein doses)
Study: 34421925
Drug: Other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapies
Study: 33043969
Drug: Vesatolimod (1-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesatolimod (1-12 mg)
Study: 33043969
Drug: Vesatolimod (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesatolimod (6 mg)
Study: 32721009
Drug: Intravenous acetaminophen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen, 1 g, starting at the beginning of surgery and repeated every 6 hours until 48 postoperative hours or hospital discharge
Study: 35873893
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C infusion (1.5 g/6 h for 4 days)
Study: 35873893
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 mg vitamin C/day for 4 days)
Study: 33177370
Drug: Attention Control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Control (video on a tablet)
Study: 34578862
Drug: 1-Kestose supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-Kestose supplementation (10 g/day for 12 weeks)
Study: 33226202
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (120 kVp and standard weight‐adapted CM dose)
Study: 39489284
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily step count
Study: 35172871
Drug: HSM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSM plus original antihypertensive regimen
Study: 35172871
Drug: Control (original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (original antihypertensive regimen only)
Study: 34462279
Drug: Levonorgestrel 52
Normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 52 mg intrauterine system (LNG‐IUS 52 mg)
Study: 32652300
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (40 mg for 14 days) + Metformin (1000 mg daily for 3 months)
Study: 32652300
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (40 mg for 14 days) + Placebo
Study: 32148744
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation with video-game based therapy for 8 weeks, 5 sessions per week
Study: 34757164
Drug: LAVmax >
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAVmax > 22.1 mL/m1.72
Study: 33245533
Drug: tamsulosin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin + mirabegron 50 mg
Study: 34743348
Drug: FPC 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPC 6.75 mg Fe IV predialyzer
Study: 34743348
Drug: FPC 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPC 6.75 mg Fe IV postdialyzer
Study: 34743348
Drug: FPC 2
Normalized name: FPC
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FPC 2 μM (110 μg Fe/L of hemodialysate)
Study: 34743348
Drug: FPC IV
Normalized name: FPC
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FPC IV infusion of 6.75 mg iron during 3 hours of HD
Study: 34092587
Drug: Fascial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascial treatment (FT)
Study: 35688442
Drug: HTX‐011 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX‐011 (400 mg bupivacaine/12 mg meloxicam) with multimodal analgesic regimen (preoperative acetaminophen, celecoxib, pregabalin, and postoperative acetaminophen and celecoxib)
Study: 33164410
Drug: Xiaoji Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoji Recipe + Rosuvastatin Calcium 10 mg·d(‐1)
Study: 33164410
Drug: Rosuvastatin Calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin Calcium 20 mg·d(‐1)
Study: 34783626
Drug: Blended Rational
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended Rational Emotive Behavior Therapy (REBT) for 12 weeks (2 hours weekly)
Study: 35723940
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide 35% solution
Study: 34865318
Drug: Acyclovir nanofiber
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir nanofiber patch
Study: 34865318
Drug: Placebo nanofiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nanofiber patch
Study: 615706097
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (EMLA)
Study: 615706097
Drug: Placebo (moisturising
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (moisturising cream)
Study: 33403727
Drug: Ciclesonide inhalation
Normalized name: Ciclesonide Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide inhalation (343 µg/actuation) solution
Study: 33403727
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 µg/actuation)
Study: 36222067
Drug: Integrated smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated smoking cessation treatment
Study: 36146946
Drug: Guarana (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guarana (125 mg/kg)
Study: 36146946
Drug: Placebo (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (65 mg/kg protein powder)
Study: 34537120
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg.kg‐1. h‐1 (Group D)
Study: 34537120
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 15 mg.kg‐1. h‐1 (Group M)
Study: 34875106
Drug: Antipsychotic monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic monotherapy
Study: 32649925
Drug: Antipsychotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics plus psychological intervention
Study: 34521466
Drug: Lycium barbarum
Normalized name: LYCIUM BARBARUM FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycium barbarum polysaccharide (LBP) supplementation capsules
Study: 34521466
Drug: Maltodextrin placebo
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin placebo capsules
Study: 616081502
Drug: topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical 0.1% fluorometholone
Study: 32621467
Drug: Lornoxicam (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (16 mg/day for 2 days)
Study: 32621467
Drug: Xefocam (lyophilisate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xefocam (lyophilisate for preparation of solution for intravenous and intramuscular injection)
Study: 32553589
Drug: Non-surgical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical management (NSM) including radiation therapy (71% of NSM), hormonal therapy (25% of NSM), and both (4% of NSM)
Study: 35867804
Drug: istaroxime 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: istaroxime 1.0 - 1.5 μg/kg/min
Study: 35656943
Drug: Pfizer-BioNTech COVID-19
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer-BioNTech COVID-19 vaccine
Study: 35317850
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injection to the vocal cord contralateral to the lesion
Study: 34971304
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of bupivacaine (3 mL of 0.5% plain bupivacaine hydrochloride)
Study: 34934307
Drug: Esmolol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 0.5 mg/kg for 5 min before anesthesia induction, maintained at 0.5 mg/kg/h
Study: 34934307
Drug: Esmolol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1.0 mg/kg for 5 min before anesthesia induction, maintained at 2.0 mg/kg/h
Study: 34934307
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.75 mL/kg/h for 5 min before anesthesia induction, maintained at 0.25 mL/kg/h
Study: 34569486
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg/day)
Study: 34569486
Drug: Rituximab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (500 mg/m2 + 2 for 6 cycles)
Study: 32126750
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of propofol (CI group)
Study: 32126750
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus injection of propofol (BI group)
Study: 35534494
Drug: Prednisolone 1
Normalized name: prednisolone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1 mg/kg/day (max 60 mg/day) alone
Study: 35534494
Drug: Prednisolone 1
Normalized name: prednisolone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1 mg/kg/day (max 60 mg/day) with methotrexate 0.3 mg/kg/week for 9 months
Study: 33908665
Drug: Nicotine mini-lozenge
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine mini-lozenge
Study: 33908665
Drug: Nicotine mini-lozenge
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine mini-lozenge + Reduction counseling